KPMG LLC to Help Accelerate Access to COVID-19 Monoclonal Antibody Therapy Treatments
August 23, 2021
NASHVILLE, Tenn. – KPMG LLP has entered into an agreement with the federal government to help accelerate access to monoclonal antibody (mAb) treatments for COVID-19 patients who are at high risk for hospitalization or death from the coronavirus, with a focus on ensuring more equitable access to treatment.
Evidence shows that mAbs, which must be infused to patients within 10 days of the onset of symptoms and are only authorized for use in those considered high risk in accordance with the FDA emergency use authorization (EUA), can be highly effective in neutralizing the COVID-19 virus in outpatient settings and in preventing the progression of the disease.
At the same time, COVID-19 has disproportionately affected underserved communities and ethnic minorities, according to the Centers for Disease Control and Prevention (CDC). Long-standing inequities in social determinants of health, such as poverty, healthcare access, housing, and education, continue to exacerbate the impacts in these groups.
In order to expand mAb access and address some of these underlying health inequities, KPMG will develop a novel prototype process to create an operational model for establishing mAb infusion centers and increasing treatment capacity for COVID-19 positive patients in high-risk communities across the United States. The process will include innovative approaches to develop, sustain, and augment infusion center capabilities that will allow patients to receive this investigational therapy in an outpatient setting as indicated for the product, while adhering to protocols to minimize infection.
Given the need for rapid prototyping and scaling of potential solutions, initial infusion centers will likely be established by leveraging an existing network of healthcare partners that are already licensed and have the experience and the equipment necessary for administering mAbs infusion therapy.
In order to achieve these objectives, the initiative will develop and deploy solutions that may include the following:
- Expansion of capacity in existing care sites with or without current infusion capabilities
- Setup of new temporary capacity (e.g., “pop-up” centers, mobile units, tents, etc.)
- Setup of new “semi-permanent” capacity (e.g., new brick & mortar locations)
- Virtual support for existing / new centers (e.g., IT support, administrative support, education & training for staff, telemedicine screeners and follow-up, etc.)
- Staff support for infusions in congregate settings (e.g. long-term care facilities)
- Infusion site access to not just the general public, but to military and their dependents
- Increased provider and patient awareness about mAbs and opportunities for use
Recognizing that each geography selected by the federal government will have unique characteristics and challenges, KPMG will partner with providers and respected community organizations; develop targeted patient and provider outreach; and create geographic-specific resources and tools for maximizing the impact of mAbs in those area.
On August 24, the TN Department of Health hosted a webinar with Dr. Jeffrey Joseph, associate director of field medical affairs for Regeneron Pharmaceuticals, and Dr. Calita Richards, director of pharmacy with the TN Department of Health, to discuss mAb treatments in Tennessee. To view the webinar, click here.